BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang GF, Qiu L, Yang SL, Wu JC, Liu TJ. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma. Biosci Rep 2020;40:BSR20193353. [PMID: 32140709 DOI: 10.1042/BSR20193353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Selvaggi F, Catalano T, Cotellese R, Aceto GM. Targeting Wnt/β-Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents. Cancers 2022;14:1912. [DOI: 10.3390/cancers14081912] [Reference Citation Analysis]
2 Lv Y, Xie X, Pu L, Wang Q, Pu S, Ai C, Liu Y, Chen J, Xiang B. Molecular Characteristics of Choledochal Cysts in Children: Transcriptome Sequencing. Front Genet 2021;12:709340. [PMID: 34413880 DOI: 10.3389/fgene.2021.709340] [Reference Citation Analysis]
3 Guo C, Liu Z, Yu Y, Chen Y, Liu H, Guo Y, Peng Z, Cai G, Hua Z, Han X, Li Z. TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma. Front Genet 2022;13:844800. [DOI: 10.3389/fgene.2022.844800] [Reference Citation Analysis]